Instillido

Lidocaine Hydrochloride, the active ingredient in Instillido, is a local anesthetic presented as a sterile solution for urethral use. It provides reversible nerve impulse blockade to reduce discomfort during urethral procedures. GNH USA supplies Instillido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Instillido, a local anesthetic, is applied to the urethral mucosa to provide temporary numbness for various urological interventions. - Urethral catheter insertion: provides local anesthesia to reduce discomfort during catheter placement. - Cystoscopic examination: numbs the urethral lining for tolerable visual inspection. - Transurethral surgery: facilitates anesthesia during minor surgical procedures. - Urethral dilatation: reduces pain associated with dilation of the urethral tract. - Urethral stent placement: offers anesthesia to improve patient comfort during stent insertion.

Common Side Effects: - Burning sensation at the application site. - Mild irritation or redness of the urethral mucosa. - Transient numbness lasting beyond the procedure. - Slight headache. Serious or Rare Side Effects: - Allergic reaction, including anaphylaxis. - Severe hypotension or cardiovascular collapse. - Cardiac arrhythmias, especially in patients with pre‑existing conduction disorders. - Central nervous system toxicity such as seizures. - Methemoglobinemia in susceptible individuals.

Instillido should be used with careful patient assessment and adherence to handling guidelines. - Allergy assessment: confirm no known hypersensitivity to lidocaine or related amide anesthetics. - Cardiac history: evaluate for conduction disorders or arrhythmias before use. - Concomitant medications: review for drugs that may potentiate local anesthetic toxicity. - Procedure planning: employ the lowest effective concentration and volume. - Pregnancy and lactation: consider risk‑benefit ratio and use only if clearly needed. - Store at ambient temperature: keep in original container, protect from light and moisture.

Lidocaine may interact with several systemic agents, requiring attention to dosage and monitoring. Major Interactions (Avoid): - Class I antiarrhythmics (e.g., quinidine): increase risk of systemic toxicity. - Beta‑blockers: may enhance cardiac depressant effects of lidocaine. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin): may raise plasma lidocaine levels. - CYP1A2 inducers (e.g., carbamazepine): may reduce lidocaine efficacy. - Other local anesthetics: cumulative toxicity risk when combined.